Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Adrenoleukodystrophy - Drugs In Development, 2022, provides an overview of the Adrenoleukodystrophy (Genetic Disorders) pipeline landscape.

Adrenoleukodystrophy is a disorder that occurs most often in males. It mainly affects the nervous system and the adrenal glands, which are small glands located on top of each kidney. Abetalipoproteinemia is also a kind of Adrenoleukodystrophy (Adrenomyeloneuropathy/ Schilder-Addison Complex) Bassen-Kornzweig syndrome is a rare disease passed down through families in which a person is unable to fully absorb dietary fats through the intestines. The disease is caused by a defect in gene that tells the body to create lipoproteins. It is sympotomized by curvature of spine, muscle weakness, decrease of vision over time. Treatment involves large doses of vitamin supplements containing fat-soluble vitamins.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Adrenoleukodystrophy - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Adrenoleukodystrophy (Genetic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Adrenoleukodystrophy (Genetic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 2, 4, 4, 2 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 2, 1 and 2 molecules, respectively.

Adrenoleukodystrophy (Genetic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Adrenoleukodystrophy (Genetic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Adrenoleukodystrophy (Genetic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Adrenoleukodystrophy (Genetic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Adrenoleukodystrophy (Genetic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Adrenoleukodystrophy (Genetic Disorders)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Adrenoleukodystrophy (Genetic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Adrenoleukodystrophy (Genetic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Overview
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Companies Involved in Therapeutics Development
Apteeus SAS
Ashvattha Therapeutics LLC
Autobahn Therapeutics Inc
bluebird bio Inc
Celularity Inc
Imstem Biotechnology Inc
MedDay SA
Minoryx Therapeutics sl
Orpheris Inc
Poxel SA
ReceptoPharm Inc
SwanBio Therapeutics Ltd
Vigil Neuroscience Inc
Viking Therapeutics Inc
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Drug Profiles
ABX-002 – Drug Profile
biotin – Drug Profile
DAR-004 – Drug Profile
dimethyl fumarate – Drug Profile
DUOC-01 – Drug Profile
elivaldogene autotemcel – Drug Profile
Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy – Drug Profile
Gene Therapy to Activate ABCD1 for Adrenoleukodystrophy – Drug Profile
IMS-001 – Drug Profile
leriglitazone hydrochloride – Drug Profile
Next-Gen D-TZD – Drug Profile
OP-101 – Drug Profile
PSC-100 – Drug Profile
PXL-065 – Drug Profile
PXL-770 – Drug Profile
RPI-78M – Drug Profile
SBT-101 – Drug Profile
TEE-886 – Drug Profile
temsirolimus – Drug Profile
VGL-101 – Drug Profile
VK-0214 – Drug Profile
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Dormant Projects
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Discontinued Products
Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Product Development Milestones
Featured News & Press Releases
Jul 20, 2022: Viking’s Phase Ib X-ALD trial has hold lifted by FDA
Jul 05, 2022: Poxel announces the publication of preclinical article on X-linked adrenoleukodystrophy for PXL770
Jul 05, 2022: Poxel announces the publication of preclinical article on X-linked adrenoleukodystrophy for PXL065
Jun 28, 2022: Poxel to present data on PXL065 at the 8th Congress of the European Academy of Neurology
Jun 28, 2022: Poxel announces its participation in upcoming investor and scientific conferences
Jun 09, 2022: Poxel announces new solid form patent for PXL065 that provides additional protection through 2041
Jun 09, 2022: FDA Advisory Committee unanimously endorses eli-cel gene therapy for cerebral adrenoleukodystrophy
Jun 07, 2022: bluebird bio announces posting of briefing documents for upcoming FDA advisory committee meeting
May 17, 2022: Poxel announces PXL065 granted Orphan Drug Designation from the U.S. FDA for X-Linked Adrenoleukodystrophy
May 17, 2022: Poxel's PXL770 granted Orphan Drug Designation from the U.S. FDA for X-Linked Adrenoleukodystrophy
Apr 24, 2022: American Academy of Neurology (AAN 2022) – Braintale showcases together with Minoryx data from its biomarker platform for disease and treatment monitoring of X-linked adrenoleukodystrophy and strengthens collaboration
Apr 11, 2022: Poxel announces PXL770 awarded FDA Fast Track Designation for X-linked Adrenoleukodystrophy
Apr 05, 2022: Autobahn Therapeutics to present new preclinical data at the 2022 American Academy of Neurology Annual Meeting
Feb 16, 2022: Poxel announces PXL065 granted FDA Fast Track Designation for X-linked adrenoleukodystrophy
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Table 1: Number of Products under Development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)), 2022
Table 2: Number of Products under Development by Companies, 2022
Table 3: Number of Products under Development by Universities/Institutes, 2022
Table 4: Products under Development by Companies, 2022
Table 5: Products under Development by Companies, 2022 (Contd..1)
Table 6: Products under Development by Universities/Institutes, 2022
Table 7: Number of Products by Stage and Target, 2022
Table 8: Number of Products by Stage and Mechanism of Action, 2022
Table 9: Number of Products by Stage and Route of Administration, 2022
Table 10: Number of Products by Stage and Molecule Type, 2022
Table 11: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Pipeline by Apteeus SAS, 2022
Table 12: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Pipeline by Ashvattha Therapeutics LLC, 2022
Table 13: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Pipeline by Autobahn Therapeutics Inc, 2022
Table 14: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Pipeline by bluebird bio Inc, 2022
Table 15: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Pipeline by Celularity Inc, 2022
Table 16: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Pipeline by Imstem Biotechnology Inc, 2022
Table 17: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Pipeline by MedDay SA, 2022
Table 18: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Pipeline by Minoryx Therapeutics sl, 2022
Table 19: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Pipeline by Orpheris Inc, 2022
Table 20: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Pipeline by Poxel SA, 2022
Table 21: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Pipeline by ReceptoPharm Inc, 2022
Table 22: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Pipeline by SwanBio Therapeutics Ltd, 2022
Table 23: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Pipeline by Vigil Neuroscience Inc, 2022
Table 24: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Pipeline by Viking Therapeutics Inc, 2022
Table 25: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Dormant Projects, 2022
Table 26: Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)) – Discontinued Products, 2022
List of Figures
Figure 1: Number of Products under Development for Adrenoleukodystrophy (X-Linked Adrenoleukodystrophy (X-ALD)), 2022
Figure 2: Number of Products under Development by Companies, 2022
Figure 3: Number of Products under Development by Universities/Institutes, 2022
Figure 4: Number of Products by Top 10 Targets, 2022
Figure 5: Number of Products by Stage and Top 10 Targets, 2022
Figure 6: Number of Products by Top 10 Mechanism of Actions, 2022
Figure 7: Number of Products by Stage and Top 10 Mechanism of Actions, 2022
Figure 8: Number of Products by Routes of Administration, 2022
Figure 9: Number of Products by Stage and Routes of Administration, 2022
Figure 10: Number of Products by Molecule Types, 2022
Figure 11: Number of Products by Stage and Top 10 Molecule Types, 2022

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings